(NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results